- FY2025 adjusted revenue framework lifted to $1.04–$1.06B, reflecting stronger milestone, licensing and supply revenue (ex‑Sanofi royalties/sales).
- Q3 2025 revenue $70M, above consensus; GAAP net loss $202M driven by non‑cash charges tied to Maryland site consolidation and debt work.
- Two $25M milestone payments tied to U.S. and EU marketing‑authorization transfers of Nuvaxovid™ to Sanofi are being recognized in Q4; $225M in Sanofi‑related milestones earned year‑to‑date.
- Cash & equivalents $778M as of Sept. 30, 2025; expense guidance for 2025 reaffirmed.
- Adjusted loss per share of $0.62 in Q3, with GAAP loss per share of $1.25.
What happened today
Novavax, Inc. (NASDAQ: NVAX) reported Q3 2025 results and raised its full‑year adjusted revenue framework to $1.04–$1.06 billion (from $1.00–$1.05 billion). Management cited momentum from licensing, supply, and milestone revenue—while excluding Sanofi‑led sales and royalties from the outlook. The company also reaffirmed 2025 operating‑expense guidance.
Revenue for the quarter came in at $70 million, above Wall Street expectations, while the GAAP net loss widened to $202 million year‑over‑year, reflecting $126 million in non‑cash charges, including $97 million related to a previously announced Maryland facility consolidation.
On a per‑share basis, Novavax posted a GAAP loss of $1.25 and an adjusted loss of $0.62 for Q3 2025.
The Sanofi effect: milestones, marketing transfers and combination programs
Novavax’s collaboration with Sanofi continues to reshape its P&L and commercial footprint. In Q4 2025, Novavax is recognizing two $25 million milestone payments after transferring marketing authorizations for Nuvaxovid™ in the EU (October) and U.S. (November 4) to Sanofi—part of the parties’ broader collaboration and license agreement. Year‑to‑date, Sanofi‑linked milestones total $225 million.
Beyond COVID‑19 commercialization, Sanofi reported preliminary positive Phase 1/2 immunogenicity and safety data evaluating Nuvaxovid in combination with both Fluzone High‑Dose and Flublok, and obtained a BARDA grant to advance a pandemic influenza candidate using Novavax’s Matrix‑M® adjuvant.
Q3 by the numbers
- Revenue: $70M (vs. $85M in Q3 2024). Mix reflected $48M recognized under the Sanofi license and $14M in supply sales; no direct Nuvaxovid product sales were recorded where Novavax remained market lead in the quarter.
- Costs/expenses: Cost of sales $21M; R&D $98M (with $46M reimbursed by partners); SG&A $32M (‑55% YoY) as commercial responsibilities transition to Sanofi.
- Non‑cash charges:$126M (incl. $97M Maryland consolidation impairment; $29M loss on debt extinguishment).
- Cash & equivalents:$778M at Sept. 30, 2025 (vs. $938M at Dec. 31, 2024).
2025 outlook (as of Nov. 6)
- Adjusted total revenue:$1.04–$1.06B (raised today). Components include $610M in Nuvaxovid product sales (majority recognized in Q1 from terminated Canada/New Zealand APAs), $35–$45M in adjusted supply sales, and $395–$405M in adjusted licensing/other revenue. Sanofi‑led sales/royalties/milestones are excluded from this framework.
- Operating expenses: Combined R&D + SG&A $505–$535M; Non‑GAAP combined $440–$460M after expected partner reimbursements.
Strategic context and what to watch
Management continues to pivot Novavax toward R&D‑centric growth and partnerships, highlighting collaborations with Sanofi, Takeda (Japan marketing) and Serum Institute of India (including R21/Matrix‑M malaria vaccine). The company says it is targeting profitability by 2027 as partnership economics compound.
Catalysts to monitor:
- Sanofi‑led commercialization of Nuvaxovid during the 2025–2026 season in the U.S. and select ex‑U.S. markets.
- Further combination‑vaccine data (Nuvaxovid + influenza) and progress of Matrix‑M®‑enabled programs, including BARDA‑supported pandemic influenza.
- Execution on cost‑reduction and site‑consolidation savings following the Maryland transactions.
NVAX stock today
As of publication time, NVAX was trading around $7.76, up roughly $0.07 intraday (≈0.9%) with a session range of $7.39–$8.03. (Time: 14:42 UTC.)
Quote sheet (for editors)
- “We have relaunched the Company with a focus on R&D and partnerships intended to position us for long‑term growth,” CEO John C. Jacobs said in today’s release announcing Q3 results and the raised outlook. ir.novavax.com
Frequently asked questions
What changed in Novavax’s 2025 outlook today?
The company raised its adjusted total revenue framework to $1.04–$1.06B (from $1.00–$1.05B) and reaffirmed expense guidance, citing milestone/license/supply momentum while excluding Sanofi‑led sales and royalties.
Why did GAAP loss widen despite the revenue beat?
Q3 included $126M of non‑cash charges (site‑consolidation impairments and debt‑refinancing impacts), driving a $202M GAAP net loss. On an adjusted basis, the company reported a $0.62 per‑share loss.
What is the status of the Sanofi partnership?
Sanofi now leads commercialization of Nuvaxovid in key markets; marketing‑authorization transfers in the EU (Oct.) and U.S. (Nov. 4) triggered two $25M milestones in Q4, part of $225M in 2025 Sanofi‑related milestones earned to date.
Sources & further reading (Nov. 6, 2025)
- Company press release and investor materials on Q3 2025 and updated guidance.
- Novavax completes U.S. marketing‑authorization transfer to Sanofi (milestone details).
- Coverage of the revenue raise and Q3 highlights.
- AP earnings snapshot (GAAP and adjusted EPS).
